The Latest Trading Price of Aarti Drugs Ltd is ₹ 365.2 as of 18 May 15:30
. The P/E Ratio of Aarti Drugs Ltd changed from 23.1 on March 2021 to 18.5 on March 2025 . This represents a CAGR of -4.34% over 5 yearsThe P/E Ratio of Lyka Labs Ltd changed from 10 on March 2022 to 45.1 on March 2025 . This represents a CAGR of 45.73% over 4 years The Market Cap of Aarti Drugs Ltd changed from ₹ 6475 crore on March 2021 to ₹ 3123 crore on March 2025 . This represents a CAGR of -13.57% over 5 yearsThe Market Cap of Lyka Labs Ltd changed from ₹ 74.59 crore on March 2021 to ₹ 360.29 crore on March 2025 . This represents a CAGR of 37.02% over 5 years The revenue of Aarti Drugs Ltd for the Mar '26 is ₹ 721.06 crore as compare to the Dec '25 revenue of ₹ 602.94 crore. This represent the growth of 19.59% The revenue of Lyka Labs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 31.89 crore. This represent the decline of -100% The ebitda of Aarti Drugs Ltd for the Mar '26 is ₹ 96.56 crore as compare to the Dec '25 ebitda of ₹ 56.26 crore. This represent the growth of 71.63% The ebitda of Lyka Labs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 2.81 crore. This represent the decline of -100% The net profit of Aarti Drugs Ltd changed from ₹ 33.27 crore to ₹ 55.26 crore over 8 quarters. This represents a CAGR of 28.88%
The net profit of Lyka Labs Ltd changed from ₹ 1.29 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00%
The Dividend Payout of Aarti Drugs Ltd changed from 9.04 % on March 2021 to 5.8 % on March 2025 . This represents a CAGR of -8.49% over 5 yearsThe Dividend Payout of Lyka Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Aarti Drugs Ltd
Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals.
The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million.
With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.
Company also operates Pinnacle Life Science Private Limited, its wholly owned subsidiary focused on formulation development.
The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra.
It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary).
About Lyka Labs Ltd
Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83.
It also added a range of ayurvedic and animal health care products over the years.
In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan.
Lyka Exports is the subsidiary of the company.
The Company is engaged in the development, manufacture and marketing of quality finished dosages.
The company offers a broad range of antibiotics used as life-savers and to treat minor infections.
FAQs for the comparison of Aarti Drugs Ltd and Lyka Labs Ltd
Which company has a larger market capitalization, Aarti Drugs Ltd or Lyka Labs Ltd?
Market cap of Aarti Drugs Ltd is 3,357 Cr while Market cap of Lyka Labs Ltd is 219 Cr
What are the key factors driving the stock performance of Aarti Drugs Ltd and Lyka Labs Ltd?
The stock performance of Aarti Drugs Ltd and Lyka Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Aarti Drugs Ltd and Lyka Labs Ltd?
As of May 18, 2026, the Aarti Drugs Ltd stock price is INR ₹367.85. On the other hand, Lyka Labs Ltd stock price is INR ₹61.5.
How do dividend payouts of Aarti Drugs Ltd and Lyka Labs Ltd compare?
To compare the dividend payouts of Aarti Drugs Ltd and Lyka Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.